PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS - 1986

This medicine is dispensed with a physician's prescription only

Fanapt Tablets 1 mg
Fanapt Tablets 2 mg
Fanapt Tablets 4 mg
Fanapt Tablets 6 mg
Fanapt Tablets 8 mg
Fanapt Tablets 10 mg
Fanapt Tablets 12 mg

Composition:
Active ingredient:
Iloperidone 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg

Each 1 mg tablet contains 53.82 mg lactose
Each 2 mg tablet contains 85.07 mg lactose
Each 4 mg tablet contains 83.07 mg lactose
Each 6 mg tablet contains 110.10 mg lactose
Each 8 mg tablet contains 166.14 mg lactose
Each 10 mg tablet contains 183.50 mg lactose
Each 12 mg tablet contains 220.20 mg lactose

For a list of inactive and allergenic ingredients, see section 6 - "Additional information".

Read this leaflet carefully in its entirety before using the medicine. This leaflet contains concise information about the medicine. If you have further questions, consult your physician or pharmacist.

This medicine has been prescribed to treat your illness. Do not pass it on to others. It may harm them even if it seems to you that their illness is similar.

Warning: Increased risk of death in elderly persons suffering from dementia
Elderly patients suffering from dementia-related psychosis and treated with antipsychotic medicines are at increased risk of death.
This medicine is not approved for the treatment of patients with dementia-related psychosis.

1. What is this medicine intended for?

Fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.
Schizophrenia is a disorder with symptoms of hearing, seeing and sensing things that are not real, mistaken beliefs, unusual suspiciousness, becoming withdrawn, incoherent speech and behavioral and emotional flatness. Patients with schizophrenia may also feel depressed, anxious, guilty and tense.
Treatment with **Fanapt Tablets** has been shown to reduce the severity and occurrence of these symptoms.

Therapeutic group: Antipsychotic medicines.

2. Before using the medicine

Do not use this medicine if:
- You are sensitive (allergic) to the active ingredient iloperidone or to any of the additional ingredients that the medicine contains (please see section 6 "Additional information").
- You suffer from a severe life-threatening allergic reaction (anaphylaxis) (please see section 4 "Side effects").
- You suffer from painful, diffuse swelling of the subcutaneous tissue (angioedema).
- When your physician considers the administration of medicinal treatment for you, the finding that **Fanapt Tablets** are linked to a prolonged QT interval must be taken into account (see "Special warnings regarding the use of the medicine"). There are a number of medicines that have been found to be associated with a prolonged QT interval, which can cause a heart rhythm disorder called torsade de pointes, a polymorphic ventricular tachycardia that could cause sudden death.
  In many instances, this information will lead to the conclusion that other medicines should be tried first.

Special warnings regarding the use of the medicine
- Elderly patients suffering from dementia -
  Fanapt Tablets are not approved for use in elderly patients suffering from dementia. These patients treated with similar medicines are at increased risk for stroke and death (see under section 4 "Side effects").
- Prolonged QT interval -
  Avoid using **Fanapt Tablets** in combination with medicines known to prolong the QT interval (see section "Drug interactions").
  The use of **Fanapt Tablets** should be avoided in patients for whom a genetic syndrome called long QT syndrome is suspected and in patients with a history of cardiac arrhythmias.
  The use of **Fanapt Tablets** should be avoided in patients with a significant history of cardiovascular disease, prolonged QT, acute myocardial infarction, heart failure or cardiac arrhythmias.
  In the event that a patient taking **Fanapt Tablets** experiences symptoms that may indicate cardiac arrhythmias, such as dizziness, palpitations or feeling faint (syncope), your physician must assess continuation of the treatment, including consideration of cardiac follow-up.

Before treatment with Fanapt Tablets, tell your physician if:
- You have been diagnosed with Neuroleptic Malignant Syndrome (NMS)
  The treatment of this syndrome includes:
  1. Immediately stopping antipsychotic medicines and other medicines that are not essential for the treatment of your current condition.
  2. Intensive symptomatic treatment and medical monitoring.
  3. Treatment of severe coexisting medical problems.
- You suffer from abnormal movements of the tongue or face (tardive dyskinesia).
- You suffer from metabolic changes - such as high blood sugar levels (hyperglycemia), changes in blood cholesterol or triglyceride levels (dyslipidemia) or if you have recently gained weight.
- You are diabetic or prone to diabetes.
- You suffer from convulsions.
- You suffer from orthostatic hypotension and feel faint (syncope): **Fanapt Tablets** can cause orthostatic hypotension accompanied by dizziness, tachycardia (rapid heartbeat) and feeling faint. Be careful when using **Fanapt Tablets** in patients with cardiovascular diseases such as: heart failure, a history of myocardial infarction, ischemia, conduction irregularity.
- You suffer from falls - **Fanapt Tablets** may cause somnolence, low blood pressure on standing up (postural hypotension) and motor and sensory instability that could lead to falls and resultant fractures or other injuries.
- You suffer or have suffered in the past from leukopenia, neutropenia, agranulocytosis.
- You suffer from hyperprolactinemia.
- You suffer from problems involving regulation of body temperature.
- You suffer from swallowing disorders (dysphagia), stomach or bowel disorders that reduce your ability to swallow or impair regular bowel function.
- You have ever had thoughts about injuring yourself or committing suicide.
- You suffer from painful and prolonged erection (priapism).
- You have the potential to develop cognitive or motor impairment.

Smoking:
No effect of smoking has been found on use of this medication.

Children and adolescents:
This medicine is not intended for children or adolescents under the age of 18 years.

Tests and follow-up:
Before you begin using this medicine, your physician will refer you to have your serum potassium and magnesium levels tested. During treatment, periodic monitoring of these tests will be performed. Hypokalemia and/or hypomagnesemia could increase the risk for prolonged QT and for cardiac arrhythmias.

Drug interactions:
If you are taking or have recently taken other medicines, including non-prescription medicines and nutritional supplements, tell your physician or pharmacist. Particularly if you are taking:
- Medicines for the treatment of infections such as: ketoconazole, itraconazole
- Antidepressants such as: fluoxetine, paroxetine
- Cough medicines such as: dextromethorphan
- Tranquilizers from the benzodiazepine family, such as: midazolam
- Medicines that prolong the QT interval:
  - Medicines that treat cardiac arrhythmias:
    Class 1A medicines such as: quinidine, procainamide
    Class III medicines such as: sotalol, amiodarone
  - Antipsychotic medicines such as: chlorpromazine, thioridazine
  - Antibiotic medicines such as: gatifloxacin, moxifloxacin
  - Any other type of medicine suspected of prolonging the QT interval, such as: pentamidine, levomethadyl acetate, methadone

Use of the medicine and food:
During treatment with **Fanapt Tablets** avoid drinking grapefruit juice, as it may affect the quantity of the medicine in the blood.
The tablet may be swallowed with or without food. Swallowing the tablet with food may assist in reducing side effects..

Use of the medicine and alcohol consumption:
During treatment with **Fanapt Tablets**, it is recommended to avoid alcohol consumption.

Pregnancy, breastfeeding and fertility:
Pregnancy:
If you are pregnant or planning to become pregnant, ask your physician whether you are allowed to take **Fanapt Tablets**.
Newborns whose mothers took antipsychotic medicines, including **Fanapt Tablets**, during the third trimester of pregnancy are at risk for developing extrapyramidal symptoms and/or neonatal withdrawal symptoms, and the symptoms need to be treated accordingly.

Breastfeeding:
There is no information about the presence of iloperidone or its metabolites in breastmilk, the effect of iloperidone on a breastfeeding child or the effect of iloperidone on breast milk production. However, due to the potential for severe side effects, do not breastfeed your baby during treatment with **Fanapt Tablets**.

Driving and operating machines:
Fanapt Tablets could impair judgement, thinking or motor skills, and could therefore affect your ability to drive or operate machinery.

Important information about some of the medicine's ingredients:
Fanapt Tablets contain lactose (a type of sugar). If you have been told by your physician that you have an intolerance to some types of sugars, consult your physician before taking **Fanapt Tablets**.

3. How should you use the medicine?

Always use this medicine according to your physician's instructions. You should check with your physician or pharmacist if you are unsure about the dosage or treatment regimen. The dosage and treatment regimen will be determined only by your physician.

The usual dosage is generally:
Starting dose of 1 mg, twice a day. Your physician will gradually increase the dosage over the first 4-7 days of treatment, in order to reduce the side effects as much as possible. For this purpose, you might be instructed to use a Titration Pack.

Following the starting dose, the usual dosage is 6-12 mg twice a day (12-24 mg per day).
The maximal dosage is 12 mg twice a day (24 mg per day).

How to take the medicine:
- Swallow the tablet whole with water or other liquid (except grapefruit juice or alcohol).
- Swallow the tablet around the same time each day.
- Do not divide the tablets.

Kidney problems:
If you have kidney problems, your physician may reduce the dose of the medicine.

How should you use the Titration Pack?
The titration pack is intended for gradual increase of the dosage at the beginning of treatment in order to prevent orthostatic hypotension due to its alpha-adrenergic blocking properties. This pack contains the tablets that you will need during the first four days of treatment.
The regimen at the start of your treatment with the Titration Pack will be determined by your physician.
Day 1 – one 1 mg tablet in the morning and one 1 mg tablet in the evening.
Day 2 – one 2 mg tablet in the morning and one 2 mg tablet in the evening.
Day 3 – one 4 mg tablet in the morning and one 4 mg tablet in the evening.
Day 4 – one 6 mg tablet in the morning and one 6 mg tablet in the evening.
After taking the Titration Pack, your physician will instruct you regarding the dose needed for continued treatment.

Do not exceed the recommended dose.

If you have accidentally taken a higher dose, you may experience sleepiness, fatigue, abnormal body movements or problems with standing or walking, low blood pressure, dizziness or palpitations.
If you have taken an overdose or if a child has accidentally swallowed the medicine, proceed immediately to a physician or a hospital emergency room and bring the medicine package with you.

If you forgot to take the medicine at the required time, do not take a double dose. Take the next dose at the regular time and consult your physician.
Adhere to the treatment regimen as recommended by your physician.
If you forgot to take the medicine for more than 3 days, consult your physician.

Even if there is an improvement in your health, do not stop treatment with this medicine or change the dosage without consulting with your physician.

Do no stop taking the medicine unless your physician has told you to stop. **If you stop taking the medicine,** your illness may return.

Do not take medicines in the dark! Check the label and the dose each time you take a medicine. Wear glasses if you need them.

If you have further questions regarding use of the medicine, consult your physician or pharmacist.

4. Side effects

As with any medicine, the use of **Fanapt Tablets** may cause side effects in some users. Do not be alarmed by the list of side effects. You may not experience any of them.

Common side effects - effects that occur in 1-10 in 100 users:
- Heart disorders - palpitations
- Eye disorders - conjunctivitis (including allergic)
- Weight loss
- Disorders of skeletal muscles and connective tissues - muscle pain, muscle spasms
- Psychiatric disorders - restlessness, aggression, delusions
- Kidney and urinary tract disorders - urinary incontinence
- Disorders of the reproductive system - erectile dysfunction

Uncommon side effects - effects that occur in 1-10 in 1,000 users:
- Blood and lymphatic system disorders - anemia, iron deficiency anemia
- Ear disorders - vertigo, ringing in the ears (tinnitus)
- Endocrine disorders - underactive thyroid gland
- Eye disorders - dry eye, eyelid inflammation, eyelid edema, eye swelling, cloudiness of the eye's lens, cataract, redness due to congestion of conjunctival blood vessels
- Digestive tract disorders - stomach inflammation, increased saliva secretion, bowel incontinence, mouth ulcers
- General disorders - edema (general, pitting, due to heart diseases), difficulty walking, thirst
- Liver disorders - gallstones
- Decreased hemoglobin levels, elevated neutrophil count, decreased hematocrit levels
- Metabolic and nutritional disorders - increased appetite, dehydration, hypokalemia (low blood potassium), fluid retention
- Nervous system disorders - pins-and-needles, tingling and burning sensation (paresthesia), psychomotor hyperactivity, restlessness, forgetfulness, involuntary rapid eye movements (nystagmus)
- Psychiatric disorders - hostility, paranoia, confusion, mania, catatonia (motor behavior characterized by significantly reduced response to one's surroundings), mood swings, panic attacks, obsessive-compulsive disorder, bulimia nervosa (an eating disorder), delirium, emotional alcohol abuse, impulse control disorders, clinical depression, reduced sex drive, anorgasmia
- Kidney and urinary tract disorders - pain while urinating, urinary frequency, wetting oneself, kidney stones
- Disorders of the reproductive system - testicular pain, amenorrhea (skipping menstrual periods), breast pain
- Disorders of the respiratory system, rib cage and chest cavity - nosebleed, asthma, runny nose, sinus congestion, dry nose

Rare side effects - effects that occur in 1-10 in 10,000 users:
- Blood and lymphatic system disorders - leukopenia
- Heart disorders - cardiac arrhythmias, first-degree atrioventricular block, heart failure (including congestive and acute)
- Digestive tract disorders - aphthae in the mouth, duodenal ulcer, hiatal hernia, excessive stomach acid secretion, lip ulcers, esophagal inflammation due to gastroesophageal reflux, inflammation of the mucosa of the mouth (stomatitis)
- General disorders - hyperthermia
- Disorders of skeletal muscles and connective tissues - twisted neck
- Nervous system disorders - restless leg syndrome
- Kidney and urinary tract disorders - urinary retention, acute kidney failure
- Disorders of the reproductive system and breasts - irregular menstrual periods, menorrhagia (heavy menstrual bleeding), bleeding between periods, postmenopausal bleeding, gynecomastia, prostatitis
- Disorders of the respiratory system, rib cage and chest cavity - dry throat, sleep apnea syndrome, shortness of breath on exertion

If a side effect occurs, if one of the side effects worsens or if you suffer from a side effect not mentioned in this leaflet, consult your physician.

Side effects can be reported to the Ministry of Health by clicking on the link "Report on Side Effects of Drug Treatment" found on the Ministry of Health homepage (www.health.gov.il) that directs you to the online form for reporting side effects, or by entering the link:
https://sideeffects.health.gov.il.

5. How should the medicine be stored?

- Avoid poisoning! This medicine and any other medicine should be kept in a closed place out of the reach and sight of children and/or infants in order to avoid poisoning. Do not induce vomiting unless explicitly instructed to do so by your physician.
- Do not use this medicine after the expiry date (exp. Date) which appears on the outer package. The expiry date refers to the last day of that month.

Storage conditions:
- Store at a temperature below 25°C.
- Store in the original package in order to protect from light and moisture. Make sure to keep the package tightly closed.
- May be used up to 45 days after first opening.

6. Additional information

- In addition to the active ingredient iloperidone, this medicine also contains: lactose monohydrate (200M), crospovidone XL (type A), microcrystalline cellulose (102), hypromellose (603), magnesium stearate (nonbovine), silica, colloidal anhydrous.
- What the medicine looks like and the contents of the package:

White, round, flat, bevel-edged tablets with no score line, imprinted with a logo on one side of the tablet and tablet dosage on the other side.
Packaged in white plastic bottles with a child resistant cap. Each bottle contains a desiccant and contains 14 / 60 / 100 tablets. Not all package sizes may be marketed.
Titration Pack: Two separate blister packs in a cardboard package, each containing four tablets: 1 mg, 2 mg, 4 mg, 6 mg.

- **Registration holder and address:** MegaPharm Ltd., P.O.B. 519, Hod Hasharon 4510501, Israel.
- **Manufacturer and address:** Patheon Inc., Mississauga, Canada **for** Vanda Pharmaceuticals, Washington, USA.
- Revised in January 2020
- Registration number of the medicine in the National Drug Registry of the Ministry of Health:

Fanapt Tablets 1 mg: 148-32-33482
Fanapt Tablets 2 mg: 148-33-33486
Fanapt Tablets 4 mg: 148-34-33487
Fanapt Tablets 6 mg: 148-35-33488
Fanapt Tablets 8 mg: 148-36-33489
Fanapt Tablets 10 mg: 152-13-34129
Fanapt Tablets 12 mg: 152-14-34130